Clinical Study of Intra Articular Injection of Catholic MASTER Cell (Bone Marrow Derived Mesenchymal Stem Cell) in Knee Osteoarthritis (MSC-OA)

Clinical Study of Intra Articular Injection of Catholic MASTER Cell (Bone Marrow Derived Mesenchymal Stem Cell) in Knee Osteoarthritis

Randomized Double-blind Clinical Study of Intra Articular Injection of Catholic MASTER Cell in Knee Osteoarthritis

objective - safety and efficacy evalaution of MASTER cells injected into knee of patients with osteoarthritis background osteoarthritis Osteoarthritis is severe and intractable musculoskeletal disease that eventually leads to joint failure and pain due to inflammation and joint injury. OA is one of the most prevalent diseases. The prevalence increases with age, but overuse and trauma can result in OA in young population as well. Injured cartilage can not be regenerated spontaneously, untreated injured cartilage eventually leads to osteoarthritis. Surgical treatment may repair the damage but the reparied cartilage may turn out to be fibrocartilage rather than hyaline cartilage. Curent treatment medical therapy: medication for symptom relief, together with exercise. Medications include NSAIDS visco-supplement. surgical therapy: total knee replacement arthroplasty to overcome such limitations, cell therapy such as stem cell/ chondrocyte injection is being investigated Hypothesis - Intra articular injection of MASTER cells will show safety and efficacy in terms of pain and functional improvement. Protocol 1) deisgn : Injection of MASTER cell 1X 10^8 cells/2cc (experimental arm) or 2cc saline (placebo arm) into knee of patients with osteoarthritis 2) outcomes primary outcome : safety evaluation(adverse event) secondary outcomes : check on 1,2,3,6,9,12 months, atient reported outcome (WOMAC, KOOS, IKDC, pain VAS) 3,12 months SF-36, knee MRI score, serum cytokine, bone turnover marker 12 months x-ray 3) Disease osteoarthritis 4) Subjects inclusion : age 20-80yrs, diagnosed with OA according to ACR criteria for knee OA, baseline pain VAS equal or more than 50mm exclusion: lower extremities surgery within 6months or planned surgery, concommitant systemic rheumatic diseases that can affect the results of the trial, steroid intraarticular inejction into the index knee within 3months, clinicallly meaningful abnormal lab tests (liver function, kidney function) 5) evaluation primary outome : compare the number and proportion of of adverse event and lab test abnormalities between the two arms secondary outome change of 100mm pain VAS change of Western Ontario and McMAster Universities Osteoarthritis (WOMAC) pain VAS, IKDC, KOOS total score change WOMAC sub scale, IKDC, KOOS chagne of KHAQ change of MRI indices change of x-ray( joins space narrowing) change of serum ESR/CRP, CTX-II

Intraarticular injection of Catholic MASTER cell, 1 time, 1 x 10^8 cells/DMEM 5cc, into knee joint of patients with osteoarthritis

Inclusion Criteria: Age 20-80 diagnosed with knee osteoarthritis (OA) according to ACR classfication criteia for knee OA symptomatic OA that lastede for at least 3 months before screening Baseline Pain VAS ≥50 mm treated with medication such as acetaminophen, tramadol, NSAID for at least 1month due to OA pain X-ray Kellgren-Lawrence grade 1~4 volauntarily enrolled with informed consent no improvement with medical treatment for at least 3 months Exclusion Criteria: disease in spine or lower extremities that can affect the outcome of index knee surgery on lower extremities within 6month before injection or planned joint symptoms that can affect the interpretation of the trial data or prevent the subject from enrollement including but not limited to symptomatic fracture, fibromyalgia, rheumatoid arthritis, reactive arthritis steroid injection to the index knee within preivious 3months hyaluronic acid injection to the index knee within preivious 6months underwent cell therapy or gene therapy in the past more than 3 times upper normal limit in one or more of the followings: serum creatinine, bilirubin, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or more than 3 times upper normal limit in two or more of the followings: bilirubin, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) participation in a different clinical trial other than this within 4 weeks after initiation of the current study use (reccuent use or addiction) of substances that can affect pain sensation such as narcotics females of childbearing age who do not consent to effective contraceptive methods during the study period pregnant or lactating woman malignancy considered to be inappropriate for the trial by investigators